APG-2449, a TKI targeting ALK, ROS1, and focal adhesion kinase (FAK), has shown anti-tumor activity in preclinical models and is currently being tested in a phase I dose escalation and expansion trial that enrolled patients with ALK/ROS1 positive NSCLC [103]. Here, ALK is linked to neoplasm.